Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Free Cash Flow: 2012-2024

Historic Free Cash Flow for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to -$136.0 million.

  • Ocular Therapeutix's Free Cash Flow fell 54.76% to -$56.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.4 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$136.0 million for FY2024, which is 78.15% down from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Free Cash Flow is -$136.0 million, which was down 78.15% from -$76.3 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Free Cash Flow ranged from a high of -$54.4 million in FY2020 and a low of -$136.0 million during FY2024.
  • Its 3-year average for Free Cash Flow is -$91.9 million, with a median of -$76.3 million in 2023.
  • Per our database at Business Quant, Ocular Therapeutix's Free Cash Flow spiked by 31.85% in 2020 and then crashed by 78.15% in 2024.
  • Ocular Therapeutix's Free Cash Flow (Yearly) stood at -$54.4 million in 2020, then declined by 22.70% to -$66.7 million in 2021, then climbed by 5.13% to -$63.3 million in 2022, then fell by 20.54% to -$76.3 million in 2023, then plummeted by 78.15% to -$136.0 million in 2024.